LACTO-N-FUCOPENTAOSE I Chemische Eigenschaften,Einsatz,Produktion Methoden

R-S?tze Betriebsanweisung:

R20/21/22:Gesundheitssch?dlich beim Einatmen,Verschlucken und Berührung mit der Haut.
R37/38:Reizt die Atmungsorgane und die Haut.
R41:Gefahr ernster Augensch?den.

S-S?tze Betriebsanweisung:

S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
S36/37/39:Bei der Arbeit geeignete Schutzkleidung,Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.

Chemische Eigenschaften

White solid

Verwenden

LNF-1 human milk saccharide, contains blood group O (H) type I determinant

Definition

ChEBI: A linear amino pentasaccharide comprising one fucose, two galactose, one glucosamine and one glucose unit (at the reducing end), linked as shown.

LACTO-N-FUCOPENTAOSE I Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

LACTO-N-FUCOPENTAOSE I Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19553	58
TargetMol Chemicals Inc.		support@targetmol.com	United States	38463	58
ShenZhen Trendseen Biological Technology Co.,Ltd.	13417589054	trendseenbio@gmail.com	China	11681	58
J & K SCIENTIFIC LTD.	010-82848833 400-666-7788	jkinfo@jkchemical.com	China	96815	76
Hunan Hui Bai Shi Biotechnology Co., Ltd.	0731-85526065 13308475853	ivy@hnhbsj.com	China	4552	62
ChemStrong Scientific Co.,Ltd	0755-0755-66853366 13670046396	sales@chem-strong.com	China	18043	56
Sichuan Wei Keqi Biological Technology Co., Ltd.	028-81700200 18116577057	3003855609@qq.com	China	7887	56
Hangzhou Dingyan Chem Co., LTD	0571-87157530-8002 15267169049	sales@dingyanchem.com	China	2190	58
Chengdu Push Bio-Technology Co., Ltd.	028-85370565-229 18080489829	3004654993@qq.com	China	8889	60
Shenzhen Polymeri Biochemical Technology Co., Ltd.	+86-400-002-6226 +86-13028896684;	sales@rrkchem.com	China	56902	58

7578-25-8()Verwandte Suche:

---

• LNF-1
• LNF I
• LNFP I
• LACTO-N-FUCOPENTAOSE-1
• LACTO-N-FUCOPENTAOSE I
• IV2FUC-LCOSE4
• LACTO-N-FUCOPENTAOSE I FROM HUMAN MILK
• α-l-fuc (1→2)-β-d-gal-(1→3)-β-d-glcnac-(1→3)-β-d-gal-(1→4)-d-glc
• N-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(2R,3S,4R,5R)-6-hydroxy-1-oxo-2,4-bis[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyhexan-3-yl]oxyoxan-3-yl]acetamide
• LNFP I, α-L-Fuc (1-2)-β-D-Gal-(1-3)-β-D-GlcNAc-(1-3)-β-D-Gal-(1-4)-D-Glc
• Lacto-N-fucopentaose I (LNFP I)
• alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp
• Lacto-N-fucopentaose Ⅰ
• ALPHA-L-FUC [1->2]-BETA-D-GAL-[1->3]-BETA-D-GLCNAC-[1->3]-BETA-D-GAL-[1->4]-D-GLC
• N-[(2S,3R,4R,5S,6R)-2-[(2R,3S,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3R,4R,5R)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl]oxyoxan-4-yl]oxy-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
• Lacto-N-neofucopentaose I (LnNFP-I)
• Blood group H antigen pentaose type 1 / Lacto-N-fucopentaose I (LNFP I)
• D-Glucose, O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-β-D-galactopyranosyl-(1→3)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→3)-O-β-D-galactopyranosyl-(1→4)-
• Fuc-a-1,2-Gal-b-1,3-GlcNAc-b-1,3-Gal-b-1,4-Glc
• Fucα1,2Galβ1,3GlcNAcβ1,3Galβ1,4Glc
• Blood group O(H) type I determinant
• D-Glucose, O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-β-D-galactopyranosyl-(1→3)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→3)-O-β-D-galactopyranosyl-(1→4)-
• Lacto-N-fucopentaose I / Blood group H antigen pentaose type 1 (LNFP-I)
• 7578-25-8
• Carbohydrate Standards
• Carbohydrate Analysis
• Carbohydrates
• BioChemical
• Biochemicals and Reagents
• Post-translational Modification
• Proteomics
• P to Q
• Proteomics and Protein Expression
• Proteasome inhibitor
• Disaccharide
• D to K
• Enzyme Inhibitors
• Enzyme Inhibitors by Enzyme
• Enzymes, Inhibitors, and Substrates
• Guanylate cyclase